Abstract

TREATMENT OF TYPE-2 DIABETES MELLITUS WITH SGLT-2 INHIBITORS AND INFLUENCE ON RENAL FUNCTION

Nikolay Krasimirov Kostadinov* and Tzvetelina TzvetanovaTotomirova

.

Abstract

Type 2 diabetes is a global problem with increasing incidence. Globally, more than one in 10 adults are now living with diabetes. It is the leading cause of chronic kidney disease (CKD) worldwide and its incidence continues to rise. CKD is associated with progressive loss of kidney function. Early stages of CKD may be reversible. Therapeutic control of diabetes is more difficult in patients with renal impairment, requiring a therapeutic approach with increased caution. There are advances in available glucose-lowering agents for the treatment of type 2 diabetes that not only modify the disease itself, but also have important benefits in terms of associated cardiovascular risk factors. Sodium glucose cotransporter 2 (SGLT2) inhibitors have demonstrated significant benefits in reducing major adverse cardiovascular events, heart failure hospitalization, mortality, plus the renoprotective benefit they provide.

Keywords: diabetes type 2, SGLT 2 inhibitors, renal function.